Role of the innate immune system in the pathogenesis of inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 48, Issue 2, 2009, Pages 142-151

  Van Lierop, Pieter P E ^a   Samsom, Janneke N ^a   Escher, Johanna C ^a   Nieuwenhuis, Edward E S ^a,b  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b NONE   (Netherlands)

Author keywords

Epithelium; Inflammatory bowel disease; Innate immune system; Microbiota; Pattern recognition receptor

Indexed keywords

ALPHA DEFENSIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CRYOPYRIN; CYTOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; PATTERN RECOGNITION RECEPTOR; PROTEIN IRAK M; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 5; TOLLIP; UNCLASSIFIED DRUG; PROBIOTIC AGENT;

ADAPTIVE IMMUNITY; CROHN DISEASE; ENTERITIS; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; MUCOSAL IMMUNITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS; ANTIBODY PRODUCTION; BACTERIAL PHENOMENA AND FUNCTIONS; IMMUNOLOGY; INTESTINE MUCOSA; MICROBIOLOGY; PHYSIOLOGY;

ANTIBODY FORMATION; BACTERIAL PHYSIOLOGICAL PHENOMENA; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; IMMUNITY, INNATE; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; PROBIOTICS; RECEPTORS, PATTERN RECOGNITION;

EID: 66149139288     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3181821964     Document Type: Review

References (188)

1. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3:521-33.
2. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
3. Hugot J-P, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
4. Nieuwenhuis EE, Escher JC. Early onset IBD: what's the difference? Dig Liver Dis 2008;40:12-5.
5. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science 2001;292:1115-8.
6. Dalziel TK. Chronic intestinal enteritis. BMJ 1913;2:1068-70.
7. Chiodini RJ, Van Kruiningen HJ, Thayer WR, et al. Possible role of mycobacteria in inflammatory bowel disease: I. An unclassified Mycobacterium species isolated from patients with Crohn's disease. Dig Dis Sci 1984;29:1073-9.
8. Autschbach F, Eisold S, Hinz U, et al. High prevalence of Mycobacterium avium subspecies paratuberculosis IS900 DNA in Gut tissues from individuals with Crohn's disease. Gut 2005;54:944-9.
9. Bull TJ, McMinn EJ, Sidi-Boumedine K, et al. Detection and verification of Mycobacterium avium subsp. paratuberculosis in fresh ileocolonic mucosal biopsy specimens from individuals with and without Crohn's disease. J Clin Microbiol 2003;41:2915-23.
10. Kobayashi K, Blaser MJ, Brown WR. Immunohistochemical examination for mycobacteria in intestinal tissues from patients with Crohn's disease. Gastroenterology 1989;96:1009-15.
11. Sartor RB. Does Mycobacterium avium subspecies paratuberculosis cause Crohn's disease? Gut 2005;54:896-8.
12. Feller M, Huwiler K, Stephan R, et al. Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis. Lancet Infect Dis 2007;7:607-13.
13. Ekbom A, Wakefield AJ, Zack M, et al. Perinatal measles infection and subsequent Crohn's disease. Lancet 1994;344:508-10.
14. Montgomery SM, Morris DL, Pounder RE, et al. Paramyxovirus infections in childhood and subsequent inflammatory bowel disease. Gastroenterology 1999;116:796-803.
15. Kangro HO, Chong SK, Hardiman A, et al. A prospective study of viral and mycoplasma infections in chronic inflammatory bowel disease. Gastroenterology 1990;98:549-53.
16. Schuller JL, Piket-van Ulsen J, Veeken IV, et al. Antibodies against Chlamydia of lymphogranuloma-venereum type in Crohn's disease. Lancet 1979;(8106):19-20.
17. Zollner B, Feucht HH, Koch H, et al. Isolation of Chlamydia trachomatis from the lower digestive tract. Infection 1993; 21:318-20.
18. Martin HM, Campbell BJ, Hart CA, et al. Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology 2004;127:80-93.
19. Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 1998;115:1405-13.
20. Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004;127:412-21.
21. Liu Y, van Kruiningen HJ, West AB, et al. Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology 1995;108:1396-404.
22. Kotlowski R, Bernstein CN, Sepehri S, et al. High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut 2007;56:669-75.
23. Weaver GA, Alpern HD, Davis JS, et al. Gastrointestinal angio-dysplasia associated with aortic valve disease: part of a spectrum of angiodysplasia of the gut. Gastroenterology 1979;77:1-11.
24. Mylonaki M, Rayment NB, Rampton DS, et al. Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:481-7.
25. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002;122:44-54.
26. Dimitroulia E, Spanakis N, Konstantinidou AE, et al. Frequent detection of cytomegalovirus in the intestine of patients with inflammatory bowel disease. Inflamm Bowel Dis 2006;12:879-84.
27. Main J, McKenzie H, Yeaman GR, et al. Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. BMJ 1988;297:1105-6.
28. Puspok A, Dejaco C, Oberhuber G, et al. Influence of Helicobacter pylori infection on the phenotype of Crohn's disease. Am J Gastroenterol 1999;94:3239-44.
29. Burke DA, Axon AT. Adhesive Escherichia coli in inflammatory bowel disease and infective diarrhoea. BMJ 1988;297:102-4.
30. Barnich N, Darfeuille-Michaud A. Adherent-invasive Escherichia coli and Crohn's disease. Curr Opin Gastroenterol 2007; 23:16-20.
31. Barnich N, Boudeau J, Claret L, et al. Regulatory and functional co-operation of flagella and type 1 pili in adhesive and invasive abilities of AIEC strain LF82 isolated from a patient with Crohn's disease. Mol Microbiol 2003;48:781-94.
32. Sitaraman SV, Klapproth JM, Moore DA 3rd et al. Elevated flagellin-specific immunoglobulins in Crohn's disease. Am J Physiol Gastrointest Liver Physiol 2005;288:G403-6.
33. Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004; 113:1296-306.
34. Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 2005; 128:2020-8.
35. Papadakis KA, Yang H, Ippoliti A, et al. Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis 2007;13:524-30.
36. Gewirtz AT, Vijay-Kumar M, Brant SR, et al. Dominant-negative TLR5 polymorphism reduces adaptive immune response to fla-gellin and negatively associates with Crohn's disease. Am J Physiol Gastrointest Liver Physiol 2006;290:G1157-63.
37. Duchmann R, Neurath M, Marker-Hermann E, et al. Immune responses towards intestinal bacteria: current concepts and future perspectives. Z Gastroenterol 1997;35:337-46.
38. Madsen KL, Malfair D, Gray D, et al. Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. Inflamm Bowel Dis 1999;5:262-70.
39. Waidmann M, Bechtold O, Frick JS, et al. Bacteroides vulgatus protects against Escherichia coli-induced colitis in gno-tobiotic interleukin-2-deficient mice. Gastroenterology 2003; 125:162-77.
40. Karrasch T, Jobin C. NF-kappaB and the intestine: friend or foe? Inflamm Bowel Dis 2007;14:114-24.
41. Dijkstra G, Yuvaraj S, Jiang HQ, et al. Early bacterial dependent induction of inducible nitric oxide synthase (iNOS) in epithelial cells upon transfer of CD45RB(high) CD4(p) T cells in a model for experimental colitis. Inflamm Bowel Dis 2007;13:1467-74.
42. Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991;338:771-4.
43. Madsen KL. Inflammatory bowel disease: lessons from the IL-10 gene-deficient mouse. Clin Invest Med 2001;24:250-7.
44. Garrett WS, Lord GM, Punit S, et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 2007;131:33-45.
45. Colombel JF, Cortot A, van Kruiningen HJ. Antibiotics in Crohn's disease. Gut 2001;48:647.
46. Mimura T, Rizzello F, Helwig U, et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 2002;16:909-17.
47. Jiang HQ, Kushnir N, Thurnheer MC, et al. Monoassociation of SCID mice with Helicobacter muridarum, but not four other enterics, provokes IBD upon receipt of T cells. Gastroenterology 2002;122:1346-54.
48. Kim SC, Tonkonogy SL, Albright CA, et al. Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology 2005; 128:891-906.
49. Mazmanian SK, Liu CH, Tzianabos AO, et al. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005;122:107-18.
50. Krinos CM, Coyne MJ, Weinacht KG, et al. Extensive surface diversity of a commensal microorganism by multiple DNA inversions. Nature 2001;414:555-8.
51. Foo MC, Lee A. Antigenic cross-reaction between mouse intestine and a member of the autochthonous microflora. Infect Immun 1974;9:1066-9.
52. Berg RD, Savage DC. Immune responses of specific pathogen-free and gnotobiotic mice to antigens of indigenous and nonindigenous microorganisms. Infect Immun 1975;11:320-9.
53. Kim SC, Tonkonogy SL, Karrasch T, et al. Dual-association of gnotobiotic Il-10-/- mice with 2 nonpathogenic commensal bacteria induces aggressive pancolitis. Inflamm Bowel Dis 2007;13:1457-66.
54. Haller D, Russo MP, Sartor RB, et al. IKK beta and phosphati-dylinositol 3-kinase/Akt participate in non-pathogenic Gram-negative enteric bacteria-induced RelA phosphorylation and NF-kappa B activation in both primary and intestinal epithelial cell lines. J Biol Chem 2002;277:38168-7.
55. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119:305-9.
56. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635-9.
57. Mallon P, McKay D, Kirk S, et al. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007:CD005573.
58. Rolfe VE, Fortun PJ, Hawkey CJ, et al. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2006:CD004826.
59. Tedelind S, Westberg F, Kjerrulf M, et al. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol 2007;13:2826-32.
60. Scheppach W, Sommer H, Kirchner T, et al. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology 1992;103:51-6.
61. Di Sabatino A, Morera R, Ciccocioppo R, et al. Oral butyrate for mildly to moderately active Crohn's disease. Aliment Pharmacol Ther 2005;22:789-94.
62. Segain JP, Raingeard de la Bletiere D, Bourreille A, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 2000;47:397-403.
63. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388:394-7.
64. Abreu MT, Arditi M. Innate immunity and toll-like receptors: clinical implications of basic science research. J Pediatr 2004; 144:421-9.
65. Medzhitov R, Preston-Hurlburt P, Kopp E, et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 1998;2:253-8.
66. Ogura Y, Inohara N, Benito A, et al. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 2001;276:4812-8.
67. Girardin SE, Boneca IG, Viala J, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003;278:8869-72.
68. Inohara N, Ogura Y, Fontalba A, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2: implications for Crohn's disease. J Biol Chem 2003;278:5509-12.
69. Hugot JP, Laurent-Puig P, Gower-Rousseau C, et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996;379:821-3.
70. Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001;357:1925-8.
71. Cuthbert AP, Fisher SA, Mirza MM, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 2002;122:867-74.
72. Martinon F, Tschopp J. Inflammatory caspases: linking an in-tracellular innate immune system to autoinflammatory diseases. Cell 2004;117:561-74.
73. Mariathasan S, Monack DM. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 2007;7:31-40.
74. Aganna E, Martinon F, Hawkins PN, et al. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 2002;46:2445-52.
75. Petrilli V, Dostert C, Muruve DA, et al. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol 2007;19:615-22.
76. Rescigno M, Nieuwenhuis EE. The role of altered microbial signaling via mutant NODs in intestinal inflammation. Curr Opin Gastroenterol 2007;23:21-6.
77. Cario E, Podolsky DK. Intestinal epithelial TOLLerance versus inTOLLerance of commensals. Mol Immunol 2005; 42:887-93.
78. Abreu MT, Vora P, Faure E, et al. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol 2001;167:1609-16.
79. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000; 68:7010-7.
80. Furrie E, Macfarlane S, Thomson G, et al. Toll-like receptors-2, -3 and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria. Immunology 2005;115:565-74.
81. Melmed G, Thomas LS, Lee N, et al. Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut. J Immunol 2003;170:1406-15.
82. Naik S, Kelly EJ, Meijer L, et al. Absence of Toll-like receptor 4 explains endotoxin hyporesponsiveness in human intestinal epithelium. J Pediatr Gastroenterol Nutr 2001;32:449-53.
83. Otte JM, Cario E, Podolsky DK. Mechanisms of cross hypor-esponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells. Gastroenterology 2004;126:1054-70.
84. Hausmann M, Kiessling S, Mestermann S, et al. Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology 2002;122:1987-2000.
85. Arranz A, Abad C, Juarranz Y, et al. Effect of VIP on TLR2 and TLR4 Expression in Lymph Node Immune Cells During TNBS-Induced Colitis [10.1196/annals.1317.001]. Ann NY Acad Sci 2006;1070:129-34.
86. Rhee SH, Im E, Riegler M, et al. Pathophysiological role of Toll-like receptor 5 engagement by bacterial flagellin in colonic inflammation. Proc Natl Acad Sci U S A 2005;102:13610-5.
87. Bambou JC, Giraud A, Menard S, et al. In vitro and ex vivo activation of the TLR5 signaling pathway in intestinal epithelial cells by a commensal Escherichia coli strain. J Biol Chem 2004;279:42984-92.
88. Gewirtz AT, Navas TA, Lyons S, et al. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol 2001; 167:1882-5.
89. Soderholm JD, Olaison G, Peterson KH, et al. Augmented increase in tight junction permeability by luminal stimuli in the non-inflamed ileum of Crohn's disease. Gut 2002;50:307-13.
90. Buhner S, Buning C, Genschel J, et al. Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation? Gut 2006;55:342-7.
91. Xiao H, Gulen MF, Qin J, et al. The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity 2007;26:461-75.
92. Wald D, Qin J, Zhao Z, et al. SIGIRR, a negative regulator of Tolllike receptor-interleukin 1 receptor signaling. Nat Immunol 2003;4:920-7.
93. Garlanda C, Riva F, Polentarutti N, et al. Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc Natl Acad Sci U S A 2004;101:3522-6.
94. Barnich N, Hisamatsu T, Aguirre JE, et al. GRIM-19 interacts with NOD2 and serves as down-stream effector of anti-bacterial function in intestinal epithelial cells. J Biol Chem 2005; 280:19021-6.
95. Ferreira AC, Gomes L, Maximo V, et al. GRIM-19 mutations are not associated with Crohn's disease. Inflamm Bowel Dis 2008; 14:434-5.
96. Sugawara K, Olson TS, Moskaluk CA, et al. Linkage to peroxi-some proliferator-activated receptor-gamma in SAMP1/YitFc mice and in human Crohn's disease. Gastroenterology 2005; 128:351-60.
97. Kelly D, Campbell JI, King TP, et al. Commensal anaerobic Gut bacteria attenuate inflammation by regulating nuclear-cytoplas-mic shuttling of PPAR-gamma and RelA. Nat Immunol 2004; 5:104-12.
98. Dubuquoy L, Jansson EA, Deeb S, et al. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 2003;124:1265-76.
99. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004;118:229-41.
100. Lee J, Mo JH, Katakura K, et al. Maintenance of colonic home-ostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nat Cell Biol 2006;8:1327-36.
101. Vijay-Kumar M, Wu H, Aitken J, et al. Activation of toll-like receptor 3 protects against DSS-induced acute colitis. Inflamm Bowel Dis 2007;13:856-64.
102. Heimesaat MM, Fischer A, Siegmund B, et al. Shift towards pro-inflammatory intestinal bacteria aggravates acute murine colitis via Toll-like receptors 2 and 4. PLoS ONE 2007;2:e662.
103. Rakoff-Nahoum S, Hao L, Medzhitov R. Role of toll-like receptors in spontaneous commensal-dependent colitis. Immunity 2006;25:319-29.
104. Burns K, Clatworthy J. Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor. Nat Cell Biol 2000; 2:346-51.
105. Zhang G, Ghosh S. Negative regulation of toll-like receptor-mediated signaling by Tollip. J Biol Chem 2002; 277:7059-65.
106. LeBouder E, Rey-Nores JE, Rushmere NK, et al. Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol 2003; 171:6680-9.
107. Kobayashi K, Hernandez LD, Galan JE, et al. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002; 110:191-202.
108. Wertz IE, O'Rourke KM, Zhou H, et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004;430:694-9.
109. Boone DL, Turer EE, Lee EG, et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004;5:1052-60.
110. Schmid M, Fellermann K, Fritz P, et al. Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease. J Leukoc Biol 2007;81:907-15.
111. Samsom JN, van der Marel AP, van Berkel LA, et al. Secretory leukoprotease inhibitor in mucosal lymph node dendritic cells regulates the threshold for mucosal tolerance. J Immunol 2007;179:6588-95.
112. Lala S, Ogura Y, Osborne C, et al. Crohn's disease and the NOD2 gene: a role for paneth cells. Gastroenterology 2003;125:47-57.
113. Ogura Y, Lala S, Xin W, et al. Expression of NOD2 in Paneth cells: a possible link to Crohn's ileitis. Gut 2003;52:1591-7.
114. Wilson CL, Ouellette AJ, Satchell DP, et al. Regulation of intestinal alpha-defensin activation by the metalloproteinase ma-trilysin in innate host defense. Science 1999;286:113-7.
115. Ayabe T, Satchell DP, Wilson CL, et al. Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. Nat Immunol 2000:113-8.
116. Tan X, Hsueh W, Gonzalez-Crussi F. Cellular localization of tumor necrosis factor (TNF)-alpha transcripts in normal bowel and in necrotizing enterocolitis: TNF gene expression by Paneth cells, intestinal eosinophils, and macrophages. Am J Pathol 1993;142:1858-65.
117. Keshav S, Lawson L, Chung LP, et al. Tumor necrosis factor mRNA localized to Paneth cells of normal murine intestinal epithelium by in situ hybridization. J Exp Med 1990;171:327-32.
118. Selsted ME, Miller SI, Henschen AH, et al. Enteric defensins: antibiotic peptide components of intestinal host defense. J Cell Biol 1992;118:929-36.
119. Rumio C, Besusso D, Palazzo M, et al. Degranulation of paneth cells via toll-like receptor 9. Am J Pathol 2004;165:373-81.
120. Wehkamp J, Harder J, Weichenthal M, et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 2004;53:1658-64.
121. Wehkamp J, Salzman NH, Porter E, et al. Reduced Paneth cell {alpha}-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A 2005;102:18129-34.
122. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005;307:731-4.
123. Tai EK, Wu WK, Wong HP, et al. A new role for cathelicidin in ulcerative colitis in mice. Exp Biol Med (Maywood) 2007; 232:799-808.
124. Marks DJ, Harbord MW, MacAllister R, et al. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 2006;367:668-78.
125. Fukata M, Michelsen KS, Eri R, et al. Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol 2005;288:G1055-6.
126. van Beelen AJ, Zelinkova Z, Taanman-Kueter EW, et al. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity 2007;27:660-9.
127. Z'GraggenK,WalzA,MazzucchelliL,etal. The C-X-C chemokine ENA-78 is preferentially expressed in intestinal epithelium in inflammatory bowel disease. Gastroenterology 1997;113:808-16.
128. Banks C, Bateman A, Payne R, et al. Chemokine expression in IBD: mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J Pathol 2003; 199:28-35.
129. Reinecker HC, Loh EY, Ringler DJ, et al. Monocyte-chemoat-tractant protein 1 gene expression in intestinal epithelial cells and inflammatory bowel disease mucosa. Gastroenterology 1995; 108:40-50.
130. Kwon JH, Keates S, Bassani L, et al. Colonic epithelial cells are a major site of macrophage inflammatory protein 3alpha (MIP-3alpha) production in normal colon and inflammatory bowel disease. Gut 2002;51:818-26.
131. Dwinell MB, Lugering N, Eckmann L, et al. Regulated production of interferon-inducible T-cell chemoattractants by human intestinal epithelial cells. Gastroenterology 2001;120:49-59.
132. Nieuwenhuis EE, Blumberg RS. The role of the epithelial barrier in inflammatory bowel disease. Adv Exp Med Biol 2006;579:108-16.
133. Watanabe T, Kitani A, Murray PJ, et al. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 2004;5:800-8.
134. Watanabe T, Kitani A, Murray PJ, et al. Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigen-specific colitis. Immunity 2006;25:473-85.
135. Netea MG, Ferwerda G, de Jong DJ, et al. Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release. J Immunol 2005;174:6518-23.
136. Netea MG, Kullberg BJ, de Jong DJ, et al. NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. Eur J Immunol 2004;34:2052-9.
137. Damen GM, Hol J, de Ruiter L, et al. Chemokine production by buccal epithelium as a distinctive feature of pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2006;42:142-9.
138. van Lierop PP, Damen GM, Escher JC, et al. Defective acute inflammation in Crohn's disease. Lancet 2006;368:578.
139. Podolsky DK, Isselbacher KJ. Composition of human colonic mucin: selective alteration in inflammatory bowel disease. J Clin Invest 1983;72:142-53.
140. Van der Sluis M, De Koning BA, De Bruijn AC, et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 2006;131:117-29.
141. Nikolaus S, Bauditz J, Gionchetti P, et al. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. Gut 1998;42:470-6.
142. Furuta GT, Nieuwenhuis EE, Karhausen J, et al. Eosinophils alter colonic epithelial barrier function: role for major basic protein. Am J Physiol Gastrointest Liver Physiol 2005;289:G890-7.
143. He SH. Key role of mast cells and their major secretory products in inflammatory bowel disease. World J Gastroenterol 2004; 10:309-18.
144. Nieuwenhuis EE, Neurath MF, Corazza N, et al. Disruption of T helper 2-immune responses in Epstein-Barr virus-induced gene 3-deficient mice. Proc Natl Acad Sci U S A 2002;99:16951-6.
145. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004;113:1490-7.
146. Heller F, Fuss IJ, Nieuwenhuis EE, et al. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002;17:629-38.
147. van Dieren JM, van der Woude CJ, Kuipers EJ, et al. Roles of CD1d-restricted NKT cells in the intestine. Inflamm Bowel Dis 2007;13:1146-52.
148. Kelsall BL, Leon F. Involvement of intestinal dendritic cells in oral tolerance, immunity to pathogens, and inflammatory bowel disease. Immunol Rev 2005;206:132-48.
149. Damen GM, van Lierop F, de Ruiter L, et al. Production of ILI2p70 and IL23 by monocyte-derived dendritic cells in children with inflammatory bowel disease. Gut 2008;57:1480.
150. Rescigno M, Urbano M, Valzasina B, et al. Dendritic cells express tight junction proteins and penetrate Gut epithelial monolayers to sample bacteria. Nat Immunol 2001;2:361-7.
151. Niess JH, Brand S, Gu X, et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 2005;307:254-8.
152. Hart AL, Al-Hassi HO, Rigby RJ, et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology 2005;129:50-65.
153. Bell SJ, Rigby R, English N, et al. Migration and maturation of human colonic dendritic cells. J Immunol 2001;166:4958-67.
154. Middel P, Raddatz D, Gunawan B, et al. Increased number of mature dendritic cells in Crohn's disease: evidence for a chemo-kine-mediated retention mechanism. Gut 2006;55:220-7.
155. Cruickshank SM, English NR, Felsburg PJ, et al. Characterization of colonic dendritic cells in normal and colitic mice. World J Gastroenterol 2005;11:6338-47.
156. Silva MA, Lopez CB, Riverin F, et al. Characterization and distribution of colonic dendritic cells in Crohn's disease. Inflamm Bowel Dis 2004;10:504-12.
157. Krajina T, Leithauser F, Moller P, et al. Colonic lamina propria dendritic cells in mice with CD4+ T cell-induced colitis. Eur J Immunol 2003;33:1073-83.
158. Karlis J, Penttila I, Tran TB, et al. Characterization of colonic and mesenteric lymph node dendritic cell subpopulations in a murine adoptive transfer model of inflammatory bowel disease. Inflamm Bowel Dis 2004;10:834-47.
159. McGovern D, Powrie F. The IL23 axis plays a key role in the pathogenesis of IBD. Gut 2007;56:1333-6.
160. Rimoldi M, Chieppa M, Salucci V, et al. Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat Immunol 2005;6:507-14.
161. Reche PA, Soumelis V, Gorman DM, et al. Human thymic stromal lymphopoietin preferentially stimulates myeloid cells. J Immunol 2001;167:336-43.
162. Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 2002;3:673-80.
163. Zaph C, Troy AE, Taylor BC, et al. Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. Nature 2007;446:552-6.
164. Rimoldi M, Chieppa M, Salucci V, et al. Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat Immunol 2005;6:507-14.
165. Kugathasan S, Saubermann LJ, Smith L, et al. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut 2007;56:1696-705.
166. Ruemmele FM, El Khoury MG, Talbotec C, et al. Characteristics of inflammatory bowel disease with onset during the first year of life. J Pediatr Gastroenterol Nutr 2006;43:603-9.
167. Eckburg PB, Relman DA. The role of microbes in Crohn's disease. Clin Infect Dis 2007;44:256-62.
168. Burnham WR, Lennard-Jones JE, Stanford JL, et al. Mycobacteria as a possible cause of inflammatory bowel disease. Lancet 1978; 2 (Pt 1):693-6.
169. McFadden JJ, Butcher PD, Chiodini R, et al. Crohn's disease-isolated mycobacteria are identical to Mycobacterium paratuber-culosis, as determined by DNA probes that distinguish between mycobacterial species. J Clin Microbiol 1987;25:796-801.
170. Czuprynski CJ, Balish E. Pathogenesis of Listeria monocytogenes for gnotobiotic rats. Infect Immun 1981;32:323-31.
171. Giaffer MH, Holdsworth CD, Duerden BI. Virulence properties of Escherichia coli strains isolated from patients with inflammatory bowel disease. Gut 1992;33:646-50.
172. Rabizadeh S, Rhee KJ, Wu S, et al. Enterotoxigenic Bacteroides fragilis: a potential instigator of colitis. Inflamm Bowel Dis 2007;13:1475-83.
173. Basset C, Holton J, Bazeos A, et al. Are Helicobacter species and enterotoxigenic Bacteroides fragilis involved in inflammatory bowel disease? Dig Dis Sci 2004;49:1425-32.
174. Prindiville TP, Sheikh RA, Cohen SH, et al. Bacteroides fragilis enterotoxin gene sequences in patients with inflammatory bowel disease. Emerg Infect Dis 2000;6:171-4.
175. Hogenauer C, Langner C, Beubler E, et al. Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. N Engl J Med 2006;355:2418-26.
176. Wei B, Huang T, Dalwadi H, et al. Pseudomonas fluorescens encodes the Crohn's disease-associated I2 sequence and T-cell superantigen. Infect Immun 2002;70:6567-75.
177. Graham DY, Yoshimura HH, Estes MK. DNA hybridization studies of the association of Pseudomonas maltophilia with inflammatory bowel diseases. J Lab Clin Med 1983; 101:940-54.
178. Muller S, Arni S, Varga L, et al. Serological and DNA-based evaluation of Chlamydia pneumoniae infection in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2006; 18:889-94.
179. Blaser MJ, Miller RA, Lacher J, et al. Patients with active Crohn's disease have elevated serum antibodies to antigens of seven enteric bacterial pathogens. Gastroenterology 1984; 87:888-94.
180. Ferrante M, Henckaerts L, Joossens M, et al. New sero-logical markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007; 56:1394-403.
181. Sendid B, Colombel JF, Jacquinot PM, et al. Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Lab Immunol 1996;3:219-26.
182. Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cy-toplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998;42:788-91.
183. Tiwana H, Walmsley RS, Wilson C, et al. Characterization of the humoral immune response to Klebsiella species in inflammatory bowel disease and ankylosing spondylitis. Br J Rheumatol 1998;37:525-31.
184. Cooper R, Fraser SM, Sturrock RD, et al. Raised titres of anti-klebsiella IgA in ankylosing spondylitis, rheumatoid arthritis, and inflammatory bowel disease. BMJ (Clin Res Ed) 1988; 296:1432-4.
185. Landers CJ, Cohavy O, Misra R, et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 2002;123:689-99.
186. Zholudev A, Zurakowski D, Young W, et al. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol 2004; 99:2235-41.
187. Sutton CL, Kim J, Yamane A, et al. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology 2000;119:23-31.
188. Spivak J, Landers CJ, Vasiliauskas EA, et al. Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease. Inflamm Bowel Dis 2006;12:1122-30.